



3<sup>rd</sup> March, 2025

## RESPIRI ENTERS PARTNERSHIP WITH EVOLENT CARE PARTNERS' (NYSE:EVH) TO DELIVER CARE MANAGEMENT SERVICES IN HAWAII

### Highlights

- *Respiri partners with Evolent Care Partners' & HIPA Medicare Shared Services Program (MSSP) in Hawaii.*
- *Evolent operations span 12 US states and serve more than 94,000 Medicare patients.*
- *Program starts with ~1,800 target patients in Hawaii*
- *Reimbursement Revenue Potential: Expected US\$100–\$200 PPPM via Respiri clinic-in-cloud model.*
- *Strengthens Respiri's position in value-based care & remote patient monitoring*
- *Patient enrollment begins April 2025.*

**Respiri Limited** (ASX:RSH; OTCQB:RSHUF) ("Respiri"), an eHealth Company supporting Connected Care Management in the USA, is pleased to announce it is partnering with **Evolent Care Partners' (Evolent NYSE:EVH)** and Hawaii Independent Physicians Association (HIPA) to deliver comprehensive Care Management services to Medicare beneficiary patients in Hawaii.

Effective January 1<sup>st</sup>, 2025, participating practices in the Hawaii Independent Physicians Association (Hawaii IPA) joined Evolent Care Partners' Medicare Shared Savings Program (MSSP) Accountable Care Organization (ACO). Evolent Care Partners' MSSP ACO was a top 1% performer for all MSSP and ACO REACH participants for the 2022 and 2023 CMS Performance Years. As part of the ACO's ongoing initiatives to improve the quality and efficiency of care provided to Medicare beneficiaries, Respiri USA, through this new partnership, will now be providing Care Management services for the ACO beneficiaries residing in Hawaii. Hawaii IPA and Respiri will work together with Evolent Care Partners to deliver a coordinated, proactive approach to care management, aiming to improve patient outcomes across the state.

Initially, Respiri will focus on the approx. 1,800 Medicare MSSP patients in the Hawaii partnership. Collaborative program planning with local market leadership has commenced with first patients' enrollment expected in April 2025. Respiri anticipates using its unique clinic-in-cloud business model to process reimbursement claims directly and anticipates generating per patient per month (pppm) reimbursement revenues of US\$100-US\$200 for services rendered. This is an evergreen agreement that is reviewed and assessed by all parties on a quarterly basis.

**Medicare Shared Savings Programs (MSSP)** in the U.S. are designed to incentivize healthcare providers to improve patient care quality while reducing unnecessary costs. These programs primarily operate through **Accountable Care Organizations (ACOs)** - groups of doctors, hospitals, and other healthcare providers that collaborate to deliver coordinated care to Medicare beneficiaries (patients). MSSP is one of the largest value-based care initiatives in the U.S., impacting millions of Medicare beneficiaries.

Marjan Mikel, Respiri CEO said, *"This partnership with Evolent and HIPA is an exciting step forward in Respiri's U.S. growth strategy. By integrating our remote monitoring technology with Evolent's value-based care expertise and working hand in glove with the HIPA providers, we are enhancing Medicare patient care in Hawaii with plans for continued broader expansion of MSSP services across the USA. This is another strong validation of our model, market opportunity and also executing against our strategic plan."*

Respiri is in advanced discussions with several major healthcare organizations and healthcare insurance companies exploring similar value-based care agreements across the U.S. These potential partnerships align with the company's growth strategy, leveraging its remote patient monitoring (RPM) technology to support cost-efficient, high-quality care for Medicare patient populations. As demand for scalable, data-driven healthcare solutions increases, Respiri remains well-positioned to expand its footprint in the U.S. market through such strategic collaborations.



For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

## About Evolent Health

Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting <https://ir.evolent.com>.

## About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.respiri.co/au](http://www.respiri.co/au)

## About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such



products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.